PGX7550: PGx Investigation of Pyrexia by Meta-Analysis of Dabrafenib/Trametinib Melanoma Studies BRF113710, BRF113929, BRF113683 and MEK115306 (200997)

Study identification

• EU PAS number:
  EUPAS7766
• Study ID:
  16870
• Official title and acronym:
  PGX7550: PGx Investigation of Pyrexia by Meta-Analysis of Dabrafenib/Trametinib Melanoma Studies BRF113710, BRF113929, BRF113683 and MEK115306 (200997)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study status:
  Finalised

Research institutions and networks

Institutions

GlaxoSmithKline (GSK)

Study timelines

Date when funding contract was signed

Planned: 21/03/2014

Actual: 21/03/2014

Study start date

Planned: 21/03/2014

Actual: 21/03/2014

Date of final study report

Planned: 31/12/2014

Actual: 17/12/2014

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

GlaxoSmithKline

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Non-EU RMP only